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Technetium-99m (99mTc) tetrofosmin is widely used in nuclear medicine as a 
diagnostic agent for myocardial perfusion and as a tumor imaging agent. As a 
parenteral preparation it requires an evaluation of its pharmacokinetics and stability 
in-vivo. Since 99mTc has a short half-life and is only available in very low 
concentrations, it is impossible to characterize its chemical properties and presence 
in the body. Due to this reason, only technetium-99 (T1/2 = 5 × 10
5 years), which is 
available in macro quantities, or natural rhenium can be used for this purpose.               
In this study rhenium-188 (188Re) tetrofosmin will be synthesized and applied, 
because non-radioactive Re can be easily obtained. Synthesis and radiochemical 
purity analysis of carrier-added 188Re-tetrofosmin were carried out as a model to 
study the in-vivo stability of technetium-99m tetrofosmin. Rhenium-188 was used 
as a tracer to identify the formation of rhenium tetrofosmin. Rhenium gluconate was 
synthesized first prior to the formation of rhenium tetrofosmin. The quality of 
labeling for both rhenium gluconate and rhenium tetrofosmin was analyzed using 
paper- and thin-layer chromatography, respectively. Rhenium gluconate can be 
synthesized with high labeling yield within 1 hour, whereas rhenium tetrofosmin 
was synthesized both in room temperature and in an elevated temperature with 
various tetrofosmin-to-rhenium mole ratios.The results showed that heating at 95C 
led to a higher yield of more than 90% within 30 minutes. Rhenium tetrofosmin 
could be produced in high radiochemical purity using an excess of tetrofosmin with 
mole ratio of 2000. It is concluded that rhenium tetrofosmin could be synthesized 
through the formation of rhenium gluconate, and a higher yield could be obtained in 
a shorter time by heating process.  
 
 
© 2015 Atom Indonesia. All rights reserved 
 
INTRODUCTION 
 
 Radiopharmaceuticals employed to detect 
myocardial perfusion, such as technetium-99m 
MIBI (
99m
Tc-MIBI) and 
99m
Tc-tetrofosmin, have 
been widely used in nuclear medicine in Indonesia,. 
MIBI or Sestamibi kits has been locally produced  
by PTRR-BATAN in colaboration with Kimia 
Farma pharmaceutical company and is initially 
marketed in Indonesia. 
99m
Tc-tetrofosmin is widely 
used and known as a newer radiopharmaceutical for 
myocardial perfusion imaging which has some 
advantages compared to 
99m
Tc-MIBI. Nowadays its 
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application has expanded to tumor imaging, as with 
99m
Tc-MIBI [1-16]. 
In hospitals (nuclear medicine department) 
sterile radiopharmaceutical kits or ”cold kits” are 
labeled with 
99m
Tc to produce 
99m
Tc-labeled 
compounds which will be administered to patients 
through intravenous injection. Afterwards, the 
exposure of gamma ray from the body will be 
detected by gamma camera to generate an image 
that will be evaluated by nuclear medicine 
specialists for diagnosis purposes [10,15,16]. 
Systemic administration of a 
radiopharmaceutical into the human body must                
be assured with regard to its safety aspects and 
benefits as parentheral preparation in general, so it 
is necessary to study its physico-chemical 
properties, mainly related to the stability and purity 
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of the radiopharmaceutical that contribute to the 
safety and efficacy in the body. Prior to patient 
study the stability of the radiopharmaceutical in the 
body should have been studied through in vitro 
studies. Therefore it is necessary to study the 
chemical stability of 
99m
Tc-tetrofosmin in vitro                      
in the blood plasma as a simulated chemical stability 
in the body over a span of imaging with a gamma 
camera [17]. 
Technetium can only be obtained in the form 
of radioactive 
99m
Tc so its physico-chemical 
properties can only be studied  through nuclear 
techniques. Since the rhenium can be obtained in 
non-radioactive form, its physico-chemical 
properties such as elucidation of the structure and 
characteristics of complex compounds can be 
studied. Because the physico-chemical properties of 
rhenium and technetium are similar, especially in 
terms of the ability to form complex with ligands, 
rhenium can be used as a model to study the 
characteristics or properties of technetium 
radiopharmaceutical [18-20]. The position of Re in 
the molecule is believed to be the same as the 
position of Tc in Tc-tetrofosmin, as can be seen in 
Fig. 1 [17]. 
 
 
Fig. 1. Chemical structure of  99mTc-tetrofosmin 
 
As with technetium complexes, to synthesize 
rhenium-ligand complexes requires a compound 
which serves as a reducing agent to lower the 
valence of rhenium from 7 so it can bind to the 
ligand to form a stable complex compounds, and the 
reducing agent commonly used is the tin(II) ion. 
Rhenium in reduced state is relatively unstable or 
more easily reoxidized (to Re(VII)) than 
technetium; therefore, it needs tin(II) chloride in a 
larger amount, and usually addition of antioxidant 
such as ascorbic acid is required to stabilize the tin. 
It indicates that rhenium is more difficult to reduce 
than technetium because its oxidation potential is 
higher [21-24]. 
Synthesis of rhenium tetrofosmin using the 
same method as for technetium-99m tetrofosmin has 
been carried out but the results were not promising. 
Efforts to improve the results have also been made 
through several modifications such as increasing the 
amount of reducing agent, changing the type of 
reducing agent, and changing the pH, but they did 
not give as good results as expected. Increasing the 
quantity of SnCl2 as reducing agent by a factor of 50 
did not make any difference, and the reaction 
solution became turbid because of the amphoteric 
Sn (II) which turned into tin hydroxide compounds 
which is poorly soluble in water [17]. 
Synthesis of Re(V) with various ligands can 
be done through the synthesis of Re-oxo-gluconate 
as precursor or intermediate complex, such as for 
tartrate, dextran, and proteins. The complex 
formation requires 1-2 hours at pH 5 using stannous 
chloride or stannous tartrate as reducing agent under 
nitrogen or argon flow to prevent oxidation of 
stannous ions and reoxidation of Re(V) to               
Re(VII) [22-35]. 
The study and preparation of carrier-free 
188
Re-tetrofosmin was done with radiochemical 
purity of over 90% and stable over 6 hours at room 
temperature [17,23]. The term carrier means an 
isotope (usually non-radioactive) that is added to the 
radioactive atoms to facilitate the reaction,                     
for example non-radioactive 
185
Re that is added to 
188
Re in the labeling process or synthesis of 
radiolabeled compound. 
Based on literature search, neither the 
research regarding carrier-added 
186/188
Re-
tetrofosmin synthesis nor the study of physico-
chemical characteristics of non-radioactive rhenium 
tetrofosmin has been done anywhere, so the 
approach which was followed to synthesize                      
non-radioactive Re-tetrofosmin in  micro scale                 
was through the route of Re-oxo-gluconate 
synthesis. 
Since the synthesis result of carrier-free 
188
Re-tetrofosmin (without non-radioactive rhenium) 
is assumed to be different from that using                         
non-radioactive rhenium or carrier-added 
186
Re/
188
Re in micro scale, in this research,                         
the reaction will be optimised by varying              
the mole ratio of tetrofosmin to perrhenate                      
and  heating the reaction mixture to increase                    
the yield of complex compound as high as                     
that of no-carrier added 
188
Re-tetrofosmin                      
(more than 90%). 
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The objective of this research is to obtain               
a protocol of rhenium-tetrofosmin synthesis in 
micro or semi-micro scale so as to be able                      
to analyze its structure and physico-chemical 
characteristics using chemical instruments instead of 
radiochemical ones. 
 
 
EXPERIMENTAL METHODS 
 
Materials and equipment 
 
The materials used are tetrofosmin (ABX), 
sodium D-gluconate (Sigma-Aldrich), stannous 
chloride dihydrate (Sigma-Aldrich), glacial                   
acetic acid (Merck), sodium acetate (Merck), 
nitrogen gas (high purity, medical grade), 
ammonium perrhenate (Merck), 
188
Re perrhenate 
solution from 
188
W/
188
Re generator (PTRR-
BATAN), basic chemicals such as acetone,                    
ethyl acetate, physiological NaCl solution (saline), 
and other materials. 
 The radiochemical purity of synthesis                
product was analysed using paper- and thin-                
layer chromatography, using Whatman-3 paper 
strips (Merck), TLC-SG strips (Merck),                      
gamma counter or gamma management                     
system (DPC), TLC scanner, glasswares and                
other equipment. 
 
 
Methods 
 
The method of synthesis was referred to                 
the method of rhenium gluconate synthesis                   
which acts as a precursor for the formation                         
of complex compounds based on rhenium                        
(V)-oxo [22-24].The synthesis of rhenium 
tetrofosmin was performed by first synthesizing    
Re-gluconate, followed by substituting gluconate 
with tetrofosmin (transchelation process).                        
The scope of work includes the preparation                     
of materials and equipment, synthesis of                        
rhenium gluconate, synthesis of rhenium 
tetrofosmin, and analysis of the radiochemical 
purity of rhenium gluconate and rhenium 
tetrofosmin using paper chromatography                      
and thin-layer chromatography. Prior to the 
synthesis of Re-tetrofosmin, the formation of              
Re-gluconate as an intermediate product was 
confirmed by analyzing it using paper 
chromatography. In the next reaction, Re-                     
gluconate was replaced by tetrofosmin, and the                   
Re-tetrofosmin formed was identified using                   
thin-layer chromatography. 
The scheme of Re-tetrofosmin synthesis                
can be seen in Fig. 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Synthesis scheme and characterization of rhenium 
tetrofosmin. 
 
The activities were carried out as follows:  
 
a. Synthesis of Re-gluconate as a precursor of the 
formation of Re-tetrofosmin  
 
Re-gluconate synthesis was performed by reacting 
sodium gluconate 0.5 M (in 0.2 M sodium               
acetate solution) with 0.04 mg of potassium 
perrhenate (1 mg/ml solution in water) to which     
was previously added a minimum of 30 µCi 
188
Re  
as a tracer. To the reaction mixture was then                    
added 0.1 ml of SnCl2 dihydrate solution                      
(20 mg/ml in 10% acetic acid) was then                      
added; the mixture was then incubated for 1-2 hours 
(Du et al., 2000). The pH of the reaction                      
should be 4-5, and it was obtained by using                
acetate buffer as the medium. Reactions                      
were performed in a sealed container with a              
nitrogen gas flow for 15 minutes, and then                        
the atmosphere containing N2 gas was                
maintained by covering the container with a balloon 
containing N2 gas. 
Analysis of Re-gluconate was carried                     
out using paper chromatography with Whatman-3 
paper as a stationary phase and acetone as                   
mobile phase (system 1) and the same method  
using physiological NaCl solution or saline                           
as the mobile phase (system 2) [22-24].                             
In system 1, Re-gluconate and rhenium                         
oxide (colloid form) stayed at the bottom (Rf = 0) 
while perrhenate ion was eluted up to the                           
front edge or solvent line (Rf = 1). In system 2,                   
Re-gluconate and perrhenate were eluted                        
nearly to the front edge (Rf = 0.8) while                                  
ReO2 colloid retained at the bottom (Rf = 0).                
 
188Re perrhenate 
 
Sodium D-gluconate  
 
 Rhenium gluconate  
 
 Rhenium tetrofosmin  
 
eluted from 188W/188Re generator 
 
 + tetrofosmin  
 
radiochemical purity  
analysis using 2 
systems of paper 
chromatography  
 
radiochemical purity  
analysis using thin 
layer chromatography  
 
+ SnCl2 
+ KReO4 
+ acetate buffer, pH 4.5 
incubated for 1 hr at RT under N2  
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The chromatograms was measured for radioactivity 
using both Gamma Management System (in which 
the strips were cut into 1 cm-long pieces                     
and put into holes at which the gamma detector 
counted the radioactivity of the strip cuts)                 
and radiochromatography scanner (at which                      
the detector ran along the whole strips to                   
measure the radioactivity). The stability of                    
Re-gluconate was also studied over elevated 
temperature.  
 
b. Synthesis of Re-tetrofosmin from Re-gluconate 
 
The process was conducted by mixing                    
an amount of Re-gluconate with 0.5 ml of an          
aliquot containing 1 mg of tetrofosmin, incubated                
at room temperature for 1-2 hours with and                
without heating in the water bath. 
The identification of Re-tetrofosmin                        
was carried out by thin-layer chromatography                 
with TLC-SG as solid phase and a mixture                          
of acetone-dichloromethane (35: 65) as mobile 
phase, in which Re colloids was retained                         
at the bottom (Rf = 0), Re perrhenate was eluted to 
the solvent line (Rf = 1), and Re-tetrofosmin                 
was eluted to the middle (Rf = 0.5) [36,37]. 
Synthesis optimization was performed by varying 
the amount of tetrofosmin, temperature, and            
reaction time. 
 
 
RESULTS AND DISCUSSION 
 
The reaction of sodium D-gluconate                      
with perrhenate using no-carrier-added 
188
Re 
resulted in the formation of 
188
Re-gluconate                     
with a 92.4% yield, where the impurity                           
was non-reduced 
188
Re or free perrhenate.                           
In this reaction, the formation of rhenium                        
oxide was not detected, indicating that the                     
reaction pH was correct so the Re reduced                     
from valence 7 to 5 was mostly reacted with 
gluconate. 
In the chromatography system with                   
acetone as eluant, 
188
Re-gluconate and 
188
ReO2                    
(Re colloid) did not migrate while 
188
ReO4
-
 (
188
Re 
perrhenate) did, whereas in the system with                   
saline 
188
Re-gluconate migrated along with                 
188
ReO4
-
 up to the solvent line (Rf = 1).                           
It indicates that acetone is less polar than                        
saline so it can elute Re-gluconate but                              
not perrhenate. On the other hand, saline                      
can elute both Re-gluconate and perrhenate at                    
Rf = 0.8 while rhenium colloid remained at                     
the bottom (Fig. 3). 
 
 
Fig. 3. The peak of 188Re-gluconate in the chromatography 
system using acetone (top) and saline as mobile phase (bottom). 
 
Heating Re-gluconate at the boiling point of                 
water (95°C) for 15 minutes decreased                          
the radiochemical purity from 89.26% to 59.5% 
(Fig. 4). It indicates that the stability became                 
lower due to reoxidation of Re(V) to Re(VII). 
 
 
 
 
Fig. 4. Effect of heating on the radiochemical stability of                
Re-gluconate. 
 
74 
Widyastuti, A.H. Gunawan / Atom Indonesia Vol. 41 No. 2  (2015) 71 - 77 
The chemical structure of Tc-tetrofosmin is 
Tc(V)-dioxo-tetrofosmin is assumed to be the same 
as that of Re-tetrofosmin since Re and Tc have 
similar physico-chemical properties. 
In the synthesis of Re-tetrofosmin from              
Re-gluconate, radiochemical purity could not be 
analyzed with TLC scanner instrument since the         
low activity of the complex was below the                     
limit of detection. The radioactivity of the 
radiochromatograms was measured using Gamma 
Management System (GMS) which is more 
sensitive. 
Radiochemical purity analysis of Re-
tetrofosmin using TLC with mixture of acetone            
and dichloromethane (35:65) as eluent should give 
peak of Re-tetrofosmin at Rf = 0.5 and perrhenate at 
Rf = 1.0, but in practice, the peaks of Re-perrhenate 
and Re-tetrofosmin were at the same spot, at                   
Rf = 1, so this method cannot distinguish between 
perrhenate and Re-tetrofosmin. From the 
observation of the presence of Re-gluconate                   
in the paper chromatogram, it was assumed that              
Re-gluconate was entirely replaced by tetrofosmin. 
In experiments using no-carrier-added 
188
Re, 
Re-gluconate was formed with a radiochemical 
purity of 100%, then after substitution                   
reaction gluconate was replaced by tetrofosmin 
within 2 hours producing Re-tetrofosmin with                 
a radiochemical purity of 90.1%. 
Transchelation process between Re-gluconate 
and tetrofosmin was performed by varying mole 
ratio between tetrofosmin and Re. The results show 
the mole ratio of tetrofosmin/Re of 2000 resulted in 
the highest yield of 60% whereas the mole ratio of 
3700 resulted in a slightly lower yield (Fig. 5). 
Thus, the mole ratio between tetrofosmin to Re                
of 2000 is recommended for the formation of                   
Re-tetrofosmin. 
 
 
 
 
Fig. 5. Effect of tetrofosmin/Re mole ratio on the radiolabeling 
yield of Re-tetrofosmin, in which Re-tetrofosmin was formed 
when mole ratio was 2000 or higher. 
Results of varying the reaction time from 30 
minutes to two hours showed that the higest yield of 
Re-tetrofosmin was obtained after one hour, while 
afterwards the yield decreased due to the instability 
of the complex, as shown in Fig. 6. In this figure, 
the presence of perrhenate as impurity is not 
displayed. 
 
 
 
Fig. 6. Effect of reaction time on the radiolabeling yield of                
Re-tetrofosmin. 
 
The substitution of gluconate by tetrofosmin 
in the reaction between Re-gluconate and 
tetrofosmin using no-carrier-added 
188
Re with 
heating in the water bath (water boiling point) for 15 
minutes resulted in a 90% yield of Re-tetrofosmin, 
but the one without heating requires a longer time 
(Fig. 7). It is considered that heating process may 
increase the enthalpy of molecules that increase the 
activation energy so the substitution reaction can 
take place more quickly. This result conformed with 
that described in the previous publication [23]. 
 
 
 
 
 
Fig. 7. Effect of heating on the yield of no-carrier-added Re- 
tetrofosmin (left peak is initial position in which Re-gluconate 
is predominant). 
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Transchelation process in experiments using 
carrier-added 
188
Re in elevated temperature showed 
that the same higher yield of 90% can be achieved 
both in 30 minutes or 1 hour, whereas in 15 minutes 
with heating and in 1 hour without heating gave 
yield of 70% and 67% respectively (Fig. 8). 
 
 
 
 
Fig. 8. Effect of heating and reaction time on the yield of 
carrier-added Re-tetrofosmin. 
 
Re-dioxo-tetrofosmin complex was formed 
through substitution of gluconate by tetrofosmin in 
the transchelation reaction. Optimization has been 
performed by varying the mole ratio between 
tetrofosmin and Re to obtain high yield of Re-
tetrofosmin and by elevating the temperature to 
accelerate the formation of the complex. 
Rhenium tetrofosmin with a radiochemical 
purity of  90% has been successfully synthesized 
using carrier-added 
188
Re. Radiochemical purity or 
labeling yield was analysed using paper 
chromatography and thin-layer chromatography. 
After 
188
Re-tetrofosmin has been successfully 
labeled, the work will proceed with synthesis of 
non-radioactive rhenium tetrofosmin in amounts 
sufficiently high to enable characterization of 
rhenium tetrofosmin using chemical instruments. 
The identification of Re-tetrofosmin in nano 
scale can be done by a method using radioactive 
188
Re which is added as a tracer. Simulation of 
stability study of 
99m
Tc-tetrofosmin in the body can 
be conducted only if Re-tetrofosmin can be 
synthesized in macro scale. It requires high amounts 
of tetrofosmin, and since tetrofosmin is expensive, 
such a study is unlikely unless the tetrofosmin                    
can be easily provided or locally synthesised.                     
To continue the stability study, it is necessary to use 
no-carrier-added radioactive rhenium in higher 
activities, so that it can still be detected                      
after dilution process to test the stability of the 
blood plasma. 
CONCLUSION 
 
Re-gluconate as a precursor for the synthesis 
of Re-tetrofosmin was produced with high 
radiochemical purity but low stability at high 
temperature.  
Re-tetrofosmin can be formed with high 
radiolabeling yield of  90% through the synthesis 
route of Re-gluconate with an excess of tetrofosmin 
and under heating. The high yield of Re-tetrofosmin 
was reached within 30 minutes with heating. It is 
suggested to apply this optimum synthesis condition 
to a larger scale using non-radioactive rhenium so 
the resulted product could be analyzed using 
conventional instrumental methods such as FTIR             
or NMR. 
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